VitaLink Research Adopts Clinical Research IO eSource, eRegulatory and CTMS System

CAMBRIDGE, Mass., May 19, 2020 /PRNewswire/ — VitaLink Research, a leading multi-therapeutic clinical trial network, has adopted the leading, fully-integrated eSource, eRegulatory and Clinical Trial Management System (CTMS) from Clinical Research IO (CRIO). VitaLink Research will use the system to collect clinical trial data electronically, enabling the sponsors and CROs they partner with to perform remote monitoring with ease, while increasing their own network’s ability to work efficiently and seamlessly across multiple site locations.

“VitaLink has always looked at how to work smarter…not harder.  With today’s challenging world, we feel that the CRIO platform will allow better access to live study data,” said Steve Clemons, VitaLink Research’s Founder and Chief Executive Officer. “Adopting ePlatforms in the industry will not only allow better patient care, but will also provide several synergies for partner CRO and Sponsor organizations.”

“We especially liked CRIO’s user-friendly interface which allows our QA/QC departments to remotely and rapidly perform full source to CRF review,” said Haley Williams, VitaLink Research’s Vice President of Quality. “Which further allows us to continue working smarter…not harder.”

“We’re delighted to welcome VitaLink Research into our community of users,” said Raymond Nomizu, CRIO’s CEO. “They are a high performing, fast growing site network, and we look forward to partnering with them as they grow and evolve their business.”

VitaLink Research plans to initiate CRIO’s eSource and eRegulatory system on all new studies, and migrate their patient and financial data to CRIO’s CTMS module.

VitaLink Research is a FULLY INTEGRATED NETWORK OF CLINICAL TRIAL SITES connecting world renowned physicians and medical professionals with site managers and research staff to create a seamless trial experience that puts the patient first and produces trustworthy, consistent results and high quality results.

Clinical Research IO is a comprehensive, Part 11 compliant technology platform for clinical research sites, with eSource, CTMS, and eRegulatory solutions. Since its launch in September 2016, over 500 research sites in 10 countries have adopted the system.

Media Contact: Raymond Nomizu, CEO
Email: 239963@email4pr.com
Address: 1 Main Street, Suite 150
Cambridge, MA 02142
Phone: (617) 302-9845

View original content to download multimedia:http://www.prnewswire.com/news-releases/vitalink-research-adopts-clinical-research-io-esource-eregulatory-and-ctms-system-301061409.html

SOURCE Clinical Research IO

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago